BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 1811226)

  • 1. [PAF-antagonists with phospholipid structure. 3. Phospholipids with heterocyclane head groups and variations of the phosphorus-nitrogen distance; synthesis, characterization and structure-activity relationship].
    Kertscher HP; Ostermann G
    Pharmazie; 1991 Nov; 46(11):772-4. PubMed ID: 1811226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [PAF-antagonists with phospholipid structure. 2. Phospholipids with heteroarene head groups and variations of the phosphorus-nitrogen distance; synthesis, characterization and structure-activity relationships].
    Kertscher HP; Ostermann G
    Pharmazie; 1991 Oct; 46(10):708-11. PubMed ID: 1803385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [PAF-antagonists with phospholipid structure. 4. Alkylcarbamoylphospholipids with heteroarene and heterocyclase head groups and variation of the P-N-distance; synthesis, characterization and structure-activity relationship].
    Kertscher HP; Schmidt B; Ostermann G
    Pharmazie; 1992 Mar; 47(3):172-4. PubMed ID: 1615020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [PAF-antagonists with a phospholipid structure. 5. Propanediol phospholipids with various substituted pyridinium and quinuclidinium head groups and variations of the phosphorus-nitrogen distance;synthesis, characterization and structure activity relationship].
    Kertscher HP; Schwabe W; Grupe R
    Pharmazie; 1993 Jan; 48(1):23-6. PubMed ID: 8460172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [PAF-antagonists with lipid structure. 6. Alkylpropandiol lipids with acyl- and ether- structures at the C-3 position and heterocyclic head groups; synthesis, characterization and structure-activity relationship].
    Kertscher HP
    Pharmazie; 1997 Sep; 52(9):672-5. PubMed ID: 9411454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [PAF-antagonists with a phospholipid structure. 1. Phospholipids with hetero-arene head groups: synthesis, characterization and determination of the action of structural elements].
    Kertscher HP; Ostermann G; Findeisen M; Limmer S; Gawrisch K
    Pharmazie; 1991 Aug; 46(8):575-9. PubMed ID: 1798710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical characterization of the interaction of lipid phosphoric acids with human platelets: comparison with platelet activating factor.
    Sugiura T; Tokumura A; Gregory L; Nouchi T; Weintraub ST; Hanahan DJ
    Arch Biochem Biophys; 1994 Jun; 311(2):358-68. PubMed ID: 8203898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and structure-activity relationship studies of novel 1-[(1-acyl-4-piperidyl)methyl]-1H-2- methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists.
    Carceller E; Merlos M; Giral M; Balsa D; García-Rafanell J; Forn J
    J Med Chem; 1996 Jan; 39(2):487-93. PubMed ID: 8558517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-activity relationships in platelet-activating factor (PAF antagonists). 6. Synthesis and in vitro antagonistic activities of 2-substituted 5-oxotetrahydrofurans.
    Favre E; Heymans F; Redeuilh C; Batt JP; Massicot F; Blavet N; Braquet P; Godfroid JJ
    J Lipid Mediat; 1992 Feb; 5(1):23-40. PubMed ID: 1449553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-activity relationships in platelet-activating factor (PAF). 5. Synthesis and in vitro antagonistic activities of ketophosphonates.
    Furno-de Winter A; Broquet C; Haelters JP; Massicot F; Sturtz G; Godfroid JJ
    J Lipid Mediat; 1991; 3(3):289-300. PubMed ID: 1773030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isolation of a phospholipid inhibitor of platelet activating factor-induced activity from perfused rat liver: identification as phosphatidylglycerol.
    Lekka M; Tokumura A; Tsuji H; Hanahan DJ
    Arch Biochem Biophys; 1993 May; 302(2):380-4. PubMed ID: 8489242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PAF-agonistic and -antagonistic behaviour of new synthetic ether phospholipids. I. Studies on blood platelets in vitro.
    Ostermann G; Hofmann B; Kertscher HP; Till U
    J Lipid Mediat; 1990; 2(1):21-31. PubMed ID: 1966804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel class of platelet activating factor (PAF) antagonists. I. Synthesis and structure-activity studies on PAF-sulfonamide isosteres.
    Tsuri T; Haga N; Matsui T; Kamata S; Kakushi H; Uchida K
    Chem Pharm Bull (Tokyo); 1992 Jan; 40(1):75-84. PubMed ID: 1605805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Synthesis and platelet aggregating activity of structural analogs of platelet-activating factor with a heterocyclic head group].
    Kertscher HP; Ostermann G
    Pharmazie; 1987 Nov; 42(11):713-5. PubMed ID: 3438334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and evaluation of antiplatelet activity of trihydroxychalcone derivatives.
    Zhao LM; Jin HS; Sun LP; Piao HR; Quan ZS
    Bioorg Med Chem Lett; 2005 Nov; 15(22):5027-9. PubMed ID: 16169724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1,5-Benzodiazepines. X. Dialkylamino substituted 1,5-benzodiazepine and [1,2,4]triazolo [4,3-a][1,5] benzodiazepine derivatives with inhibitory activity on PAF-induced platelet aggregation.
    Di Braccio M; Roma G; Grossi GC; Leoncini G; Maresca M
    Farmaco; 1992 Jan; 47(1):77-90. PubMed ID: 1616579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluation of novel steroid-modified ether phospholipids.
    Karantonis HC; Pitsinos EN; Antonopoulou S; Couladouros EA; Demopoulos CA
    Chem Phys Lipids; 2005 Dec; 138(1-2):12-9. PubMed ID: 16202400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-activity relationship studies on chalcone derivatives: potent inhibition of platelet aggregation.
    Ko HH; Hsieh HK; Liu CT; Lin HC; Teng CM; Lin CN
    J Pharm Pharmacol; 2004 Oct; 56(10):1333-7. PubMed ID: 15482650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of specific antagonists on PAF-induced platelet aggregation and release of plasminogen activator.
    Hofmann B; Ostermann G; Hoffmann A; Klöcking HP; Kertscher HP
    Biomed Biochim Acta; 1988; 47(10-11):S157-60. PubMed ID: 3248103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proaggregatory and inhibitory effects of 2-O-ethyl analogues of platelet-activating factor (PAF) on human and rabbit platelets.
    Hofmann B; Ostermann G; Kertscher HP; Till U
    Thromb Res; 1988 Feb; 49(4):415-23. PubMed ID: 3381200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.